SCHEMBL2333693

SCHEMBL2333693

O=C1CCc2c1cccc2-c1ccccc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
RECQL P46063 1/20 0.50
KMT2A Q03164 1/20 0.50
MCL1 Q07820 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
ALDH1A1 P00352 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
S100A4 P26447 2/20 0.47
PTPRC P08575 1/20 0.47
PTPN1 P18031 1/20 0.44
HSD17B10 Q99714 2/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
STAT6 P42226 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18329006 0.90 MAPT (0.47) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL35211484 0.90 MAPT (0.56) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL166701 0.90 MAPT (0.56) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL14548995 0.82 TSHR (0.46) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL16625981 0.81 MAPT (0.51) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL16131516 0.80 MAPT (0.51) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL768880 0.79 MAPT (0.53) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL4573599 0.79 MAPT (0.53) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL16098756 0.79 LMNA (0.47) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL16446362 0.79 CASP6 (0.50) MAPTKMT2ATDP1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, INC. (US) 2018-11-27 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20160368872-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS PANACELA LABS, INC. 2016-12-22 US disclosed
US-20160368872-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS PANACELA LABS, INC. 2016-12-22 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
CN-102203063-A Carbazole compounds and therapeutic uses of the compounds INCURON LLC 2011-09-28 CN disclosed
EP-2356093-A1 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (RU) 2011-08-17 EP disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 MAPT 1792/4885RECQL 1350/4885KMT2A 3680/4885
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds MALT1, PAICS, BCL9 MAPT 1792/4885RECQL 1350/4885KMT2A 3680/4885
US-20160368872-A1 COMPOUNDS AND METHODS FOR TREATING CANCERS KLK3, AR, BRDT MAPT 3369/4885RECQL 4829/4885KMT2A 1813/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT MAPT 1806/4885RECQL 1537/4885KMT2A 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.